{"id":168,"date":"2023-11-10T10:00:00","date_gmt":"2023-11-10T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=168"},"modified":"2025-09-03T02:16:54","modified_gmt":"2025-09-03T02:16:54","slug":"china-bd-2023-eccogene-and-astrazeneca-enters-a-2-billion-usd-license-on-glp-1ra-ecc5004-azd5004","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/168.html","title":{"rendered":"[China BD 2023] Eccogene and AstraZeneca enters a 2 billion USD license on GLP-1RA ECC5004 (AZD5004)"},"content":{"rendered":"\n<p>Announced Date: 2023-11-09 (November 9, 2023)<\/p>\n\n\n\n<p>Asset Name: ECC5004\uff08AZD5004\uff09<\/p>\n\n\n\n<p>Licensor: Eccogene (China)<\/p>\n\n\n\n<p>Licensee (Buyer): AstraZeneca\uff08UK\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small \u00a0Molecule, oral once-daily<\/p>\n\n\n\n<p>Asset Target: GLP-1RA (glucagon-like peptide 1 receptor agonist) <\/p>\n\n\n\n<p>Potential Indication: obesity, type-2 diabetes and other cardiometabolic conditions<\/p>\n\n\n\n<p>Current Stage: Phase I clinical trial\u00a0, US\/China<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>AstraZeneca is granted exclusive global rights for the development and commercialisation of Eccogene\u2019s ECC5004 small molecule GLP-1RA for any indication in all territories except China, where Eccogene has the right to co-develop and co-commercialise in China alongside AstraZeneca.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Eccogene will receive:<\/p>\n\n\n\n<p>Upfront payment of\u00a0 $185 million;<\/p>\n\n\n\n<p>Clinical, regulatory, and commercial\u00a0milestone payments of up to $1.825 billion;<\/p>\n\n\n\n<p>Total up to $2.01 billion.<\/p>\n\n\n\n<p>Tiered royalties on product net sales.\u00a0<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/agreement-with-eccogene-for-clinical-stage-glp-1ra.html\">AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-11-09 (November 9, 2023) Asset Name: ECC5004\uff08AZD5004\uff09 Licensor: Eccogene (China) Licensee (Buyer): AstraZeneca\uff08UK\uff09 . &hellip; <a title=\"[China BD 2023] Eccogene and AstraZeneca enters a 2 billion USD license on GLP-1RA ECC5004 (AZD5004)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/168.html\"><span class=\"screen-reader-text\">[China BD 2023] Eccogene and AstraZeneca enters a 2 billion USD license on GLP-1RA ECC5004 (AZD5004)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-168","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=168"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/168\/revisions"}],"predecessor-version":[{"id":169,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/168\/revisions\/169"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}